Muqeem Ahmed, UK,
The suspension of AstraZeneca vaccine trial or testing is a short of blow to the manufacturer. According to Oxford University, the trial has been postponed until further data on vaccines and blood clotting cases are available.
The European Medicines Agency (EMA) has directed that rare cases of blood clotting, cerebral hemorrhage and platelet depletion be listed as side effects or unexpected reactions to the vaccine.
The ENA has taken a detailed look at the blood clots that have been reported in the last two weeks under the age of 60. So far, a total of 62 cases have been reported, 24 of which, were from the European Union and the United Kingdom.
The EMA has made it clear that the vaccine is extremely beneficial, but that medical staff should be consulted immediately in response to any side effects.
The WHO says the benefits of vaccines outweigh the disadvantages Dozens of countries have approved vaccines for their citizens. While millions of doses of AstraZeneca have been safely administered worldwide, Germany, France and the Netherlands have suspended their senior citizens from using it until the results are known.
This post was originally published on VOSA.
